Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

BACKGROUND: This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatment-experienced patients. METHODS: Patients who had...

Descripción completa

Detalles Bibliográficos
Autores principales: Gane, Edward J., DeJesus, Edwin, Janczewska, Ewa, George, Jacob, Diago, Moises, Da Silva, Mariliza Hendrique, Reesink, Henk, Nikitin, Igor, Hinrichsen, Holger, Bourgeois, Stefan, Ferenci, Peter, Shukla, Umesh, Kalmeijer, Ronald, Lenz, Oliver, Fevery, Bart, Corbett, Chris, Beumont, Maria, Jessner, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457573/
https://www.ncbi.nlm.nih.gov/pubmed/28577353
http://dx.doi.org/10.1186/s12879-017-2444-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457573/
https://www.ncbi.nlm.nih.gov/pubmed/28577353
http://dx.doi.org/10.1186/s12879-017-2444-3

Ejemplares similares